Network Pharmacology Analysis and Screening of Key Active Components in NuanXin Formula for Inhibiting Osteoclast Differentiation in Osteoporosis
Advances in Traditional Chinese Medicine · 2026
DOI: 10.48014/atcm.20260702001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Traditional Chinese Medicine, 2026. Verfasst von Baichuan ZHANG und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Objective
To screen the key active components of NuanXin Formula (NX) that inhibit osteoclast (OCs) differentiation and exert anti-osteoporosis (OP) effects, and to evaluate their inhibitory effects on OCs differentiation in vitro.
Methods
Liquid chromatography-mass spectrometry (LC-MS) combined with network pharmacology was employed to identify and screen potential active components of NX. An OCs differentiation model was established by inducing RAW264. 7 cells with the receptor activator of nuclear factor-κB ligand (RANKL) . The CCK-8 assay was performed to assess the effects of NX extract and individual monomeric components on the viability of RAW264. 7 cells. Tartrate-resistant acid phosphatase (TRAP) staining and activity assays were utilized to evaluate the impact of NX extract and its key active components on OCs differentiation.
Results
LC-MS analysis identified 277 compounds in NX. Network pharmacology analysis revealed that four compounds—Osthole, 5, 7-Dihydroxy-4-methylcoumarin (D4M) , Lauric acid, and 1, 8-Cineole—were closely associated with OP-related targets. Cellular experiments showed that NX extract (0. 5-8mg/mL) inhibited RANKL-induced OCs differentiation in a dose-dependent manner (P
Zitieren
APA
ZHANG, B., XIA, W., SONG, D., & JIN, F. (2026). Network Pharmacology Analysis and Screening of Key Active Components in NuanXin Formula for Inhibiting Osteoclast Differentiation in Osteoporosis. Advances in Traditional Chinese Medicine. https://doi.org/10.48014/atcm.20260702001
Vancouver
ZHANG B, XIA W, SONG D, JIN F. Network Pharmacology Analysis and Screening of Key Active Components in NuanXin Formula for Inhibiting Osteoclast Differentiation in Osteoporosis. Advances in Traditional Chinese Medicine. 2026. doi:10.48014/atcm.20260702001
BibTeX
@article{ZHANG2026,
author = {ZHANG, Baichuan and XIA, Wenqing and SONG, Delong and JIN, Fujun},
title = {Network Pharmacology Analysis and Screening of Key Active Components in NuanXin Formula for Inhibiting Osteoclast Differentiation in Osteoporosis},
journal = {Advances in Traditional Chinese Medicine},
year = {2026},
doi = {10.48014/atcm.20260702001}
}
EUVIMED